PortViewPortView
Vicore Pharma Holding AB logo

Vicore Pharma Holding AB (VCRE) Stock Analysis

NASDAQHealthcareBiotechnology

$10.98-0.82%
1-year price historyRange $11.03 – $16.25
52-week range$10.98
$10.50$17.80

What Vicore Pharma Holding AB does

Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The company was founded in 2000 sand is headquartered in Stockholm, Sweden.

Key metrics

Market cap
$3.09B
Beta
0.15
Dividend yield
0.00%
Revenue / share
$0.00
50-day avg
$12.10
200-day avg
$12.10
52-week high
$17.80
52-week low
$10.50
CEO
Ahmed Mousa

ETFs linked to VCRE

Broad-market and Healthcare sector ETFs an investor holding Vicore Pharma Holding AB is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how VCRE fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze VCRE in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Vicore Pharma Holding AB?
Vicore Pharma Holding AB trades under the ticker VCRE on NASDAQ.
Which exchange is VCRE listed on?
VCRE is listed on NASDAQ.
What sector does Vicore Pharma Holding AB operate in?
Vicore Pharma Holding AB is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze VCRE in a portfolio?
PortView shows VCRE's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.